TScan Therapeutics (TCRX) Receivables - Net (2023)
TScan Therapeutics (TCRX) posted quarterly Receivables - Net of $31.9 million for Q2 2023.
TScan Therapeutics (TCRX) Receivables - Net (2023) Analysis & Trends
TScan Therapeutics (TCRX) has reported Receivables - Net for 1 consecutive years, with $31.9 million the latest figure, recorded in Q2 2023.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 138.93 Bn | 131.08 Bn | 2.84 Bn |
| 2 | Regeneron Pharmaceuticals | 86.11 Bn | 78.11 Bn | 3.93 Bn |
| 3 | Argenx Se | 65.43 Bn | 60.25 Bn | 1.37 Bn |
| 4 | Moderna | 56.09 Bn | 50.96 Bn | 52.00 Mn |
| 5 | BeOne Medicines | 42.13 Bn | 37.03 Bn | 1.53 Bn |
| 6 | Alnylam Pharmaceuticals | 31.61 Bn | 28.30 Bn | 992.69 Mn |
| 7 | BioNTech SE | 27.68 Bn | 9.29 Bn | 668.28 Mn |
| 8 | Insmed | 27.49 Bn | 26.32 Bn | 358.27 Mn |
| 9 | Royalty Pharma | 27.36 Bn | 26.52 Bn | - |
| 10 | TScan Therapeutics | 101.01 Mn | 101.01 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2023 | 31.93 Mn |
| Jun 30, 2023 | 31.93 Mn |